Which document records the identity, purity, and strength of investigational products to be used in the trial?

Prepare for the ICH Good Clinical Practice (GCP) Exam for Certified Clinical Research Coordinator with engaging multiple-choice questions and detailed explanations. Elevate your understanding and expertise to excel in your certification exam!

Multiple Choice

Which document records the identity, purity, and strength of investigational products to be used in the trial?

Explanation:
Verifying the investigational product’s quality before use is essential, and the Certificate of Analysis serves exactly that purpose. It is the official document that records the product’s identity, purity, and strength (potency) by presenting the analytical test results for the batch. Along with details like the lot number, expiry date, and storage conditions, the CoA confirms the product meets its predefined specifications and is suitable for use in the trial. This document is used during batch release and for traceability to ensure the exact lot used in the study matches what was validated. Shipping records show the movement and receipt of the product, but they do not certify its analytical characteristics. Decoding procedures pertain to blinding in trials, not product quality data. The master randomization list governs participant assignment, not the investigational product's quality attributes.

Verifying the investigational product’s quality before use is essential, and the Certificate of Analysis serves exactly that purpose. It is the official document that records the product’s identity, purity, and strength (potency) by presenting the analytical test results for the batch. Along with details like the lot number, expiry date, and storage conditions, the CoA confirms the product meets its predefined specifications and is suitable for use in the trial. This document is used during batch release and for traceability to ensure the exact lot used in the study matches what was validated.

Shipping records show the movement and receipt of the product, but they do not certify its analytical characteristics. Decoding procedures pertain to blinding in trials, not product quality data. The master randomization list governs participant assignment, not the investigational product's quality attributes.

Subscribe

Get the latest from Passetra

You can unsubscribe at any time. Read our privacy policy